Antipsychotics and Digestive Disorders: ANSM Issues Warning About Severe Complications from Constipation

Introduction

Neuroleptics, commonly referred to as antipsychotics, are a class of medications that are essential for many individuals diagnosed with psychiatric disorders. However, one recurring side effect remains largely underestimated in ongoing medical care: constipation.

The French National Agency for Medicines and Health Products Safety (ANSM) warns that this digestive disorder, though seemingly minor, has the potential to progress to serious clinical complications. These deteriorations in health can even prove fatal in the absence of prompt and appropriate medical treatment.

In response to this public health issue, health authorities are focusing on the entire healthcare continuum. Doctors, pharmacists, as well as patients and their immediate families, are urged to remain highly vigilant to prevent any worsening of initial symptoms.

Mechanism of Action and Common Prescriptions

Neuroleptics are prescribed as part of treatment protocols targeting specific conditions, such as schizophrenia, bipolar disorder, and certain particularly severe forms of depression. Their use also extends to the management of certain neurological disorders and the treatment of severe agitation.

The medical community has long recognized these medications’ ability to slow the natural functioning of the intestinal system. This physiological change stems from the molecules’ intrinsic anticholinergic properties, which directly reduce the frequency and intensity of contractions in the digestive tract.

The clinical consequence of this drug action is an overall slowing of bowel transit, allowing constipation to develop insidiously over the course of treatment. While the majority of episodes remain moderate, a fraction of cases progressively worsens to the point of becoming a medical emergency.

The official alert from the National Medicines Safety Agency

In an official statement released on June 11, 2026, the ANSM highlights a concerning trend regarding the recurrence of incidents linked to these psychiatric and neurological prescriptions. The agency notes that severe clinical cases continue to be reported to pharmacovigilance services, despite the numerous warnings already included in the drug information leaflets.

The health agency emphasizes the potential severity of the situation, noting that constipation caused by antipsychotic medication can lead to major gastrointestinal complications. These severe impairments of bowel function are formally identified as causes of death in specific medical contexts.

To highlight the persistence of this risk among patients, the health authority is being transparent about recently collected data. “Serious cases continue to be reported to us,” the ANSM notes in its safety bulletin.

Clinical signs requiring prompt medical attention

The progression of these digestive disorders generally follows a gradual pattern that requires close monitoring, particularly in patients who have been taking antipsychotics for several weeks. Initial symptoms are often limited to less regular bowel movements, followed by the onset of abdominal pain, a bloated stomach, or a prolonged absence of bowel movements—symptoms that warrant prompt medical attention.

The ANSM has established a list of clinical criteria requiring particular vigilance on the part of healthcare providers and patients undergoing treatment. Warning signs include, in particular, severe constipation, persistent abdominal pain, the onset of unexplained diarrhea, or an abnormally distended abdomen.

This clinical picture may be accompanied by vomiting or episodes of fever associated with these same digestive symptoms. The onset of one or more of these symptoms may require urgent hospital care to rule out the risk of serious intestinal complications.

Vulnerability of Older Adults and Drug Interactions

Exposure to these gastrointestinal risks is not limited exclusively to individuals being treated for severe psychiatric disorders. Analysis of pharmacovigilance data from the ANSM clearly indicates that patients aged 60 and older are more sensitive to the anticholinergic effects of these treatments.

The level of risk increases significantly when multiple medications known to cause constipation are prescribed together. The simultaneous administration of certain antidepressants, medications for Parkinson’s disease, or antispasmodics is likely to amplify this adverse side effect.

This complex phenomenon of drug interactions warrants a comprehensive and rigorous approach to prescribing. Healthcare professionals are strongly encouraged to conduct a thorough assessment of all medications their patients are taking before initiating any new neuroleptic therapy.

Preventive Measures and Daily Management of Treatment

Managing this iatrogenic risk relies on adopting simple preventive measures that can be easily integrated into patients’ daily routines. The ANSM’s primary recommendation is to stay hydrated by drinking enough fluids throughout the day and to optimize dietary fiber intake through regular consumption of fruits, vegetables, and whole grains.

These dietary adjustments should be accompanied by physical activity appropriate to the patient’s overall health, as well as regular monitoring of bowel movements. It is also recommended to report any symptoms perceived as unusual to your primary care physician or pharmacist without delay.

Finally, experts issue a critical safety guideline regarding the management of drug therapy. Neuroleptic treatment should never be discontinued or modified without first consulting a doctor, even if digestive problems arise, as the primary goal remains to identify early warning signs to prevent a medical emergency.

Answers to Frequently Asked Questions About Treatment

Patient education also involves clarifying several common questions related to this specific class of medications. Constipation is, in fact, very common when taking antipsychotics; it is a known side effect whose severity varies depending on individual metabolic profiles and the specific medications prescribed.

Regarding the identification of signs of severity, the onset of abdominal pain, a prolonged absence of bowel movements, abdominal bloating, vomiting, or unexplained diarrhea must prompt a medical consultation. These symptoms form the basis for the early diagnosis of potentially severe complications.

Finally, the recommended course of action in cases of slowed bowel transit strictly prohibits any independent interruption of medication. Healthcare professionals unanimously emphasize that only the prescribing physician is authorized to recommend appropriate measures to restore bowel function without compromising the patient’s psychiatric or neurological balance.

Source: passeportsante.net

Antipsychotics and Digestive Disorders: ANSM Issues Warning About Severe Complications from Constipation